X
API Suppliers
US DMFs Filed
CEP/COS Certifications
JDMFs Filed
Other Certificates
0
Other Suppliers
0
USA (Orange Book)
0
Europe
Canada
0
Australia
South Africa
Uploaded Dossiers
0
U.S. Medicaid
0
Annual Reports
0
0
1. Hydrochloride, Mianserin
2. Lerivon
3. Mianserin
4. Mianserin Monohydrochloride
5. Monohydrochloride, Mianserin
6. Org Gb 94
7. Tolvon
1. 21535-47-7
2. Mianserin Hcl
3. Mianserine Hydrochloride
4. Athymil
5. Bolvidon
6. Tolvon
7. Org Gb 94
8. Mianserin (hydrochloride)
9. Lerivon
10. Tetramide
11. Mianserine Hcl
12. 1,2,3,4,10,14b-hexahydro-2-methyldibenzo[c,f]pyrazino[1,2-a]azepine Hydrochloride
13. Mls000069681
14. 2-methyl-1,2,3,4,10,14b-hexahydrodibenzo[c,f]pyrazino[1,2-a]azepine Hydrochloride
15. Org Gb-94 Hcl
16. Nsc-759590
17. Smr000058472
18. Org-gb 94
19. 2x03tn217s
20. 1,2,3,4,10,14b-hexahydro-2-methyldibenzo(c,f)-pyrazino(1,2-a)azepine Monohydrochloride
21. Dibenzo(c,f)pyrazino(1,2-a)azepine, 1,2,3,4,10,14b-hexahydro-2-methyl-, Monohydrochloride
22. Tolvin
23. 1,2,3,4,10,14b-hexahydro-2-methyldibenzo(c,f)pyrazino(1,2-a)azepine Hydrochloride
24. Chebi:31843
25. Sr-01000000185
26. C18h20n2.hcl
27. Gb 94
28. Tetramide (tn)
29. Prestwick_514
30. Einecs 244-426-7
31. Mianserin Hydrochloride [usan:jan]
32. Mfcd00055072
33. (.+-.)-athymil
34. Opera_id_1505
35. (.+-.)-norval
36. Cid_68551
37. Mls001148213
38. Mls002222220
39. Schembl340474
40. Spectrum2300292
41. Unii-2x03tn217s
42. Chembl544428
43. Mianserin Hydrochloride Solution
44. Mianserin For System Suitability
45. Bdbm31005
46. Hy-b0188a
47. Dtxsid30944145
48. Hms1568c20
49. Pharmakon1600-02300292
50. Bcp09259
51. Mianserin Hydrochloride (jan/usan)
52. Mianserin Hydrochloride [mi]
53. Tox21_500744
54. Ccg-39108
55. Mianserin Hydrochloride [jan]
56. Nsc292267
57. Nsc759590
58. S1382
59. Mianserin Hydrochloride [usan]
60. Akos015902308
61. Cs-2079
62. Ks-5096
63. Lp00744
64. Mianserin Hydrochloride [mart.]
65. Nsc 759590
66. Nsc-292267
67. Mianserin Hydrochloride [who-dd]
68. Ncgc00094086-01
69. Ncgc00094086-02
70. Ncgc00094086-03
71. Ncgc00094086-04
72. Ncgc00261429-01
73. Ac-25005
74. Bm166416
75. Db-045611
76. Eu-0100744
77. M2623
78. Sw196707-3
79. Mianserin Hydrochloride [ep Monograph]
80. C74052
81. D01358
82. M 2525
83. 535m477
84. A912434
85. Sr-01000000185-2
86. Sr-01000000185-4
87. Sr-01000000185-8
88. W-111733
89. Q27114695
90. Mianserin Hydrochloride 1.0 Mg/ml In Methanol (as Free Base)
91. Mianserin Hydrochloride, Analytical Standard, For Drug Analysis
92. Mianserin Hydrochloride, European Pharmacopoeia (ep) Reference Standard
93. 1,2,3,4,10,14b-hexahydro-2-methyldi Benzo[c,f]pyrazino[1,2-a]azepine Hydrochloride
94. 1,2,3,4,10,14b-hexahydro-2-methyldibenzo[c,f]pyryzino[1,2-a]azepine Hydrochloride
95. 2-methyl-1,2,3,4,10,14b-hexahydrodibenzo[c,f]pyrazino[1,2-a]azepinehydrochloride
96. Mianserin For System Suitability, European Pharmacopoeia (ep) Reference Standard
97. 5-methyl-2,5-diazatetracyclo[13.4.0.0^{2,7.0^{8,13]nonadeca-1(19),8,10,12,15,17-hexaene;hydrochloride
98. 5-methyl-2,5-diazatetracyclo[13.4.0.02,7.08,13]nonadeca-1(19),8,10,12,15,17-hexaene;hydrochloride
99. 78644-54-9
100. Dibenzo[c,f]pyrazino[1,2-a]azepine, 1,2,3,4,10,14b-hexahydro-2-methyl-, Hydrochloride (1:1)
101. Hydron;5-methyl-2,5-diazatetracyclo[13.4.0.02,7.08,13]nonadeca-1(19),8,10,12,15,17-hexaene;chloride
102. Mianserin Hydrochloride Solution, 1.0 Mg/ml In Methanol (as Free Base), Ampule Of 1 Ml, Certified Reference Material
| Molecular Weight | 300.8 g/mol |
|---|---|
| Molecular Formula | C18H21ClN2 |
| Hydrogen Bond Donor Count | 1 |
| Hydrogen Bond Acceptor Count | 2 |
| Rotatable Bond Count | 0 |
| Exact Mass | 300.1393264 g/mol |
| Monoisotopic Mass | 300.1393264 g/mol |
| Topological Polar Surface Area | 6.5 Ų |
| Heavy Atom Count | 21 |
| Formal Charge | 0 |
| Complexity | 342 |
| Isotope Atom Count | 0 |
| Defined Atom Stereocenter Count | 0 |
| Undefined Atom Stereocenter Count | 1 |
| Defined Bond Stereocenter Count | 0 |
| Undefined Bond Stereocenter Count | 0 |
| Covalently Bonded Unit Count | 2 |
Adrenergic alpha-Antagonists
Drugs that bind to but do not activate alpha-adrenergic receptors thereby blocking the actions of endogenous or exogenous adrenergic agonists. Adrenergic alpha-antagonists are used in the treatment of hypertension, vasospasm, peripheral vascular disease, shock, and pheochromocytoma. (See all compounds classified as Adrenergic alpha-Antagonists.)
Antidepressive Agents, Second-Generation
A structurally and mechanistically diverse group of drugs that are not tricyclics or monoamine oxidase inhibitors. The most clinically important appear to act selectively on serotonergic systems, especially by inhibiting serotonin reuptake. (See all compounds classified as Antidepressive Agents, Second-Generation.)
Histamine H1 Antagonists
Drugs that selectively bind to but do not activate histamine H1 receptors, thereby blocking the actions of endogenous histamine. Included here are the classical antihistaminics that antagonize or prevent the action of histamine mainly in immediate hypersensitivity. They act in the bronchi, capillaries, and some other smooth muscles, and are used to prevent or allay motion sickness, seasonal rhinitis, and allergic dermatitis and to induce somnolence. The effects of blocking central nervous system H1 receptors are not as well understood. (See all compounds classified as Histamine H1 Antagonists.)
Serotonin Antagonists
Drugs that bind to but do not activate serotonin receptors, thereby blocking the actions of serotonin or SEROTONIN RECEPTOR AGONISTS. (See all compounds classified as Serotonin Antagonists.)
Market Place
